Thursday, October 13, 2016

Dyazide





Dosage Form: capsule
Dyazide®

(hydrochlorothiazide/triamterene)

Capsules

Dyazide Description


Each capsule of Dyazide (hydrochlorothiazide and triamterene) for oral use, with opaque red cap and opaque white body, contains hydrochlorothiazide 25 mg and triamterene 37.5 mg, and is imprinted with the product name Dyazide and SB. Hydrochlorothiazide is a diuretic/antihypertensive agent and triamterene is an antikaliuretic agent.


Hydrochlorothiazide is slightly soluble in water. It is soluble in dilute ammonia, dilute aqueous sodium hydroxide, and dimethylformamide. It is sparingly soluble in methanol.


Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide, and its structural formula is:



At 50°C, triamterene is practically insoluble in water (less than 0.1%). It is soluble in formic acid, sparingly soluble in methoxyethanol, and very slightly soluble in alcohol.


Triamterene is 2, 4, 7-triamino-6-phenylpteridine and its structural formula is:



Inactive ingredients consist of benzyl alcohol, cetylpyridinium chloride, D&C Red No. 33, FD&C Yellow No. 6, gelatin, glycine, lactose, magnesium stearate, microcrystalline cellulose, povidone, polysorbate 80, sodium starch glycolate, titanium dioxide, and trace amounts of other inactive ingredients.


Capsules of Dyazide meet Drug Release Test 3 as published in the current USP monograph for Triamterene and Hydrochlorothiazide Capsules.



Dyazide - Clinical Pharmacology


Dyazide is a diuretic/antihypertensive drug product that combines natriuretic and antikaliuretic effects. Each component complements the action of the other. The hydrochlorothiazide component blocks the reabsorption of sodium and chloride ions, and thereby increases the quantity of sodium traversing the distal tubule and the volume of water excreted. A portion of the additional sodium presented to the distal tubule is exchanged there for potassium and hydrogen ions. With continued use of hydrochlorothiazide and depletion of sodium, compensatory mechanisms tend to increase this exchange and may produce excessive loss of potassium, hydrogen, and chloride ions. Hydrochlorothiazide also decreases the excretion of calcium and uric acid, may increase the excretion of iodide, and may reduce glomerular filtration rate. The exact mechanism of the antihypertensive effect of hydrochlorothiazide is not known.


The triamterene component of Dyazide exerts its diuretic effect on the distal renal tubule to inhibit the reabsorption of sodium in exchange for potassium and hydrogen ions. Its natriuretic activity is limited by the amount of sodium reaching its site of action. Although it blocks the increase in this exchange that is stimulated by mineralocorticoids (chiefly aldosterone), it is not a competitive antagonist of aldosterone and its activity can be demonstrated in adrenalectomized rats and patients with Addison’s disease. As a result, the dose of triamterene required is not proportionally related to the level of mineralocorticoid activity, but is dictated by the response of the individual patients, and the kaliuretic effect of concomitantly administered drugs. By inhibiting the distal tubular exchange mechanism, triamterene maintains or increases the sodium excretion and reduces the excess loss of potassium, hydrogen and chloride ions induced by hydrochlorothiazide. As with hydrochlorothiazide, triamterene may reduce glomerular filtration and renal plasma flow. Via this mechanism it may reduce uric acid excretion although it has no tubular effect on uric acid reabsorption or secretion. Triamterene does not affect calcium excretion. No predictable antihypertensive effect has been demonstrated for triamterene.


Duration of diuretic activity and effective dosage range of the hydrochlorothiazide and triamterene components of Dyazide are similar. Onset of diuresis with Dyazide takes place within 1 hour, peaks at 2 to 3 hours and tapers off during the subsequent 7 to 9 hours.


Dyazide is well absorbed.


Upon administration of a single oral dose to fasted normal male volunteers, the following mean pharmacokinetic parameters were determined:
























AUC(0-48)


ng*hrs/mL


(± SD)

Cmax


ng/mL


(± SD)

Median


Tmax


Hrs

Ae


Mg


(± SD)
Triamterene148.7 (87.9)46.4 (29.4)1.12.7 (1.4)
hydroxytriamterene   sulfate1,865 (471)720 (364)1.319.7 (6.1)
hydrochlorothiazide834 (177)135.1 (35.7)2.014.3 (3.8)

where AUC(0-48), Cmax, Tmax and Ae represent area under the plasma concentration versus time plot, maximum plasma concentration, time to reach Cmax, and amount excreted in urine over 48 hours.


A capsule of Dyazide is bioequivalent to a single-entity 25 mg hydrochlorothiazide tablet and 37.5 mg triamterene capsule used in the double-blind clinical trial below (see Clinical Trials).


In a limited study involving 12 subjects, coadministration of Dyazide with a high-fat meal resulted in: (1) an increase in the mean bioavailability of triamterene by about 67% (90% confidence interval = 0.99, 1.90), p-hydroxytriamterene sulfate by about 50% (90% confidence interval = 1.06, 1.77), hydrochlorothiazide by about 17% (90% confidence interval = 0.90, 1.34); (2) increases in the peak concentrations of triamterene and p-hydroxytriamterene; and (3) a delay of up to 2 hours in the absorption of the active constituents.



Clinical Trials


A placebo-controlled, double-blind trial was conducted to evaluate the efficacy of Dyazide. This trial demonstrated that Dyazide (25 mg hydrochlorothiazide/37.5 mg triamterene) was effective in controlling blood pressure while reducing the incidence of hydrochlorothiazide-induced hypokalemia. This trial involved 636 patients with mild to moderate hypertension controlled by hydrochlorothiazide 25 mg daily and who had hypokalemia (serum potassium <3.5 mEq/L) secondary to the hydrochlorothiazide. Patients were randomly assigned to 4 weeks’ treatment with once-daily regimens of 25 mg hydrochlorothiazide plus placebo, or 25 mg hydrochlorothiazide combined with one of the following doses of triamterene: 25 mg, 37.5 mg, 50 mg, or 75 mg.


Blood pressure and serum potassium were monitored at baseline and throughout the trial. All five treatment groups had similar mean blood pressure and serum potassium concentrations at baseline (mean systolic blood pressure range: 137±14 mmHg to 140±16 mmHg; mean diastolic blood pressure range: 86±9 mmHg to 88±8 mmHg; mean serum potassium range: 2.3 to 3.4 mEq/L with the majority of patients having values between 3.1 and 3.4 mEq/L).


While all triamterene regimens reversed hypokalemia, at week 4 the 37.5 mg regimen proved optimal compared with the other tested regimens. On this regimen, 81% of the patients had a significant (p<0.05) reversal of hypokalemia vs. 59% of patients on the placebo/hydrochlorothiazide regimen. The mean serum potassium concentration on 37.5 mg triamterene went from 3.2±0.2 mEq/L at baseline to 3.7±0.3 mEq/L at week 4, a significantly greater (p<0.05) improvement than that achieved with placebo/hydrochlorothiazide (i.e., 3.2±0.2 mEq/L at baseline and 3.5±0.4 mEq/L at week 4). Also, 51% of patients in the 37.5 mg triamterene group had an increase in serum potassium of ≥0.5 mEq/L at week 4 vs. 33% in the placebo group. The 37.5 mg triamterene/25 mg hydrochlorothiazide regimen also maintained control of blood pressure; mean supine systolic blood pressure at week 4 was 138±21 mmHg while mean supine diastolic blood pressure was 87±13 mmHg.



Indications and Usage for Dyazide


This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.


Dyazide is indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.


Dyazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked.


Dyazide may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since Dyazide may enhance the action of these agents, dosage adjustments may be necessary.



Usage in Pregnancy


The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.


Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate.



Contraindications



Antikaliuretic Therapy and Potassium Supplementation


Dyazide should not be given to patients receiving other potassium-sparing agents such as spironolactone, amiloride, or other formulations containing triamterene. Concomitant potassium-containing salt substitutes should also not be used.


Potassium supplementation should not be used with Dyazide except in severe cases of hypokalemia. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.



Impaired Renal Function


Dyazide is contraindicated in patients with anuria, acute and chronic renal insufficiency or significant renal impairment.



Hypersensitivity


Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication.



Hyperkalemia


Dyazide should not be used in patients with preexisting elevated serum potassium.



Warnings




Hyperkalemia: Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing diuretic combinations, including Dyazide. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients first receiving Dyazide, when dosages are changed or with any illness that may influence renal function.




If hyperkalemia is suspected (warning signs include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, and shock), an electrocardiogram (ECG) should be obtained. However, it is important to monitor serum potassium levels because hyperkalemia may not be associated with ECG changes.


If hyperkalemia is present, Dyazide should be discontinued immediately and a thiazide alone should be substituted. If the serum potassium exceeds 6.5 mEq/liter more vigorous therapy is required. The clinical situation dictates the procedures to be employed. These include the intravenous administration of calcium chloride solution, sodium bicarbonate solution, and/or the oral or parenteral administration of glucose with a rapid-acting insulin preparation. Cationic exchange resins such as sodium polystyrene sulfonate may be orally or rectally administered. Persistent hyperkalemia may require dialysis.


The development of hyperkalemia associated with potassium-sparing diuretics is accentuated in the presence of renal impairment (see CONTRAINDICATIONS section). Patients with mild renal functional impairment should not receive this drug without frequent and continuing monitoring of serum electrolytes. Cumulative drug effects may be observed in patients with impaired renal function. The renal clearances of hydrochlorothiazide and the pharmacologically active metabolite of triamterene, the sulfate ester of hydroxytriamterene, have been shown to be reduced and the plasma levels increased following administration of Dyazide to elderly patients and patients with impaired renal function.


Hyperkalemia has been reported in diabetic patients with the use of potassium-sparing agents even in the absence of apparent renal impairment. Accordingly, serum electrolytes must be frequently monitored if Dyazide is used in diabetic patients.



Metabolic or Respiratory Acidosis


Potassium-sparing therapy should also be avoided in severely ill patients in whom respiratory or metabolic acidosis may occur. Acidosis may be associated with rapid elevations in serum potassium levels. If Dyazide is employed, frequent evaluations of acid/base balance and serum electrolytes are necessary.



Acute Myopia and Secondary Angle-Closure Glaucoma


Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.


Precautions

Diabetes


Caution should be exercised when administering Dyazide to patients with diabetes, since thiazides may cause hyperglycemia, glycosuria, and alter insulin requirements in diabetes. Also, diabetes mellitus may become manifest during thiazide administration.



Impaired Hepatic Function


Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate hepatic coma in patients with severe liver disease. Potassium depletion induced by the thiazide may be important in this connection. Administer Dyazide cautiously and be alert for such early signs of impending coma as confusion, drowsiness, and tremor; if mental confusion increases discontinue Dyazide for a few days. Attention must be given to other factors that may precipitate hepatic coma, such as blood in the gastrointestinal tract or preexisting potassium depletion.



Hypokalemia


Hypokalemia is uncommon with Dyazide; but, should it develop, corrective measures should be taken such as potassium supplementation or increased intake of potassium-rich foods. Institute such measures cautiously with frequent determinations of serum potassium levels, especially in patients receiving digitalis or with a history of cardiac arrhythmias. If serious hypokalemia (serum potassium less than 3.0 mEq/L) is demonstrated by repeat serum potassium determinations, Dyazide should be discontinued and potassium chloride supplementation initiated. Less serious hypokalemia should be evaluated with regard to other coexisting conditions and treated accordingly.



Electrolyte Imbalance


Electrolyte imbalance, often encountered in such conditions as heart failure, renal disease or cirrhosis of the liver, may also be aggravated by diuretics and should be considered during therapy with Dyazide when using high doses for prolonged periods or in patients on a salt-restricted diet. Serum determinations of electrolytes should be performed, and are particularly important if the patient is vomiting excessively or receiving fluids parenterally. Possible fluid and electrolyte imbalance may be indicated by such warning signs as: dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal symptoms.



Hypochloremia


Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.



Renal Stones


Triamterene has been found in renal stones in association with the other usual calculus components. Dyazide should be used with caution in patients with a history of renal stones.



Laboratory Tests


Serum Potassium

The normal adult range of serum potassium is 3.5 to 5.0 mEq per liter with 4.5 mEq often being used for a reference point. If hypokalemia should develop, corrective measures should be taken such as potassium supplementation or increased dietary intake of potassium-rich foods.


Institute such measures cautiously with frequent determinations of serum potassium levels. Potassium levels persistently above 6 mEq per liter require careful observation and treatment. Serum potassium levels do not necessarily indicate true body potassium concentration. A rise in plasma pH may cause a decrease in plasma potassium concentration and an increase in the intracellular potassium concentration. Discontinue corrective measures for hypokalemia immediately if laboratory determinations reveal an abnormal elevation of serum potassium.


Discontinue Dyazide and substitute a thiazide diuretic alone until potassium levels return to normal.


Serum Creatinine and BUN

Dyazide may produce an elevated blood urea nitrogen level, creatinine level or both. This apparently is secondary to a reversible reduction of glomerular filtration rate or a depletion of intravascular fluid volume (prerenal azotemia) rather than renal toxicity; levels usually return to normal when Dyazide is discontinued. If azotemia increases, discontinue Dyazide. Periodic BUN or serum creatinine determinations should be made, especially in elderly patients and in patients with suspected or confirmed renal insufficiency.


Serum PBI

Thiazide may decrease serum PBI levels without sign of thyroid disturbance.


Parathyroid Function

Thiazides should be discontinued before carrying out tests for parathyroid function. Calcium excretion is decreased by thiazides. Pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy. The common complications of hyperparathyroidism such as bone resorption and peptic ulceration have not been seen.



Drug Interactions


Angiotensin-converting Enzyme Inhibitors

Potassium-sparing agents should be used with caution in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to an increased risk of hyperkalemia.


Oral Hypoglycemic Drugs

Concurrent use with chlorpropamide may increase the risk of severe hyponatremia.


Nonsteroidal Anti-inflammatory Drugs

A possible interaction resulting in acute renal failure has been reported in a few patients on Dyazide when treated with indomethacin, a nonsteroidal anti-inflammatory agent. Caution is advised in administering nonsteroidal anti-inflammatory agents with Dyazide.


Lithium

Lithium generally should not be given with diuretics because they reduce its renal clearance and increase the risk of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy with Dyazide.


Surgical Considerations

Thiazides have been shown to decrease arterial responsiveness to norepinephrine (an effect attributed to loss of sodium). This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Thiazides have also been shown to increase the paralyzing effect of nondepolarizing muscle relaxants such as tubocurarine (an effect attributed to potassium loss); consequently caution should be observed in patients undergoing surgery.


Other Considerations

Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect.


Thiazides may add to or potentiate the action of other antihypertensive drugs. See INDICATIONS AND USAGE for concomitant use with other antihypertensive drugs.


The effect of oral anticoagulants may be decreased when used concurrently with hydrochlorothiazide; dosage adjustments may be necessary.


Dyazide may raise the level of blood uric acid; dosage adjustments of antigout medication may be necessary to control hyperuricemia and gout.


The following agents given together with triamterene may promote serum potassium accumulation and possibly result in hyperkalemia because of the potassium-sparing nature of triamterene, especially in patients with renal insufficiency: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium).


Exchange resins, such as sodium polystyrene sulfonate, whether administered orally or rectally, reduce serum potassium levels by sodium replacement of the potassium; fluid retention may occur in some patients because of the increased sodium intake.


Chronic or overuse of laxatives may reduce serum potassium levels by promoting excessive potassium loss from the intestinal tract; laxatives may interfere with the potassium-retaining effects of triamterene.


The effectiveness of methenamine may be decreased when used concurrently with hydrochlorothiazide because of alkalinization of the urine.



Drug/Laboratory Test Interactions


Triamterene and quinidine have similar fluorescence spectra; thus, Dyazide will interfere with the fluorescent measurement of quinidine.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Carcinogenesis

Long-term studies have not been conducted with Dyazide (the triamterene/hydrochlorothiazide combination), or with triamterene alone.



Hydrochlorothiazide


Two-year feeding studies in mice and rats, conducted under the auspices of the National Toxicology Program (NTP), treated mice and rats with doses of hydrochlorothiazide up to 600 and 100 mg/kg/day, respectively. On a body-weight basis, these doses are 600 times (in mice) and 100 times (in rats) the Maximum Recommended Human Dose (MRHD) for the hydrochlorothiazide component of Dyazide at 50 mg/day (or 1.0 mg/kg/day based on 50 kg individuals). On the basis of body-surface area, these doses are 56 times (in mice) and 21 times (in rats) the MRHD. These studies uncovered no evidence of carcinogenic potential of hydrochlorothiazide in rats or female mice, but there was equivocal evidence of hepatocarcinogenicity in male mice.


Mutagenesis

Studies of the mutagenic potential of Dyazide (the triamterene/hydrochlorothiazide combination), or of triamterene alone have not been performed.



Hydrochlorothiazide


Hydrochlorothiazide was not genotoxic in in vitro assays using strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 of Salmonella typhimurium (the Ames test); in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations; or in in vivo assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained in the in vitro CHO Sister Chromatid Exchange (clastogenicity) test, and in the mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide of 43 to 1300 mcg/mL. Positive test results were also obtained in the Aspergillus nidulans nondisjunction assay, using an unspecified concentration of hydrochlorothiazide.


Impairment of Fertility

Studies of the effects of Dyazide (the triamterene/hydrochlorothiazide combination), or of triamterene alone on animal reproductive function have not been conducted.



Hydrochlorothiazide


Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg/day, respectively, prior to mating and throughout gestation. Corresponding multiples of the MRHD are 100 (mice) and 4 (rats) on the basis of body-weight and 9.4 (mice) and 0.8 (rats) on the basis of body-surface area.



Pregnancy: Category C


Teratogenic Effects

Dyazide


Animal reproduction studies to determine the potential for fetal harm by Dyazide have not been conducted. However, a One Generation Study in the rat approximated composition of Dyazide by using a 1:1 ratio of triamterene to hydrochlorothiazide (30:30 mg/kg/day); there was no evidence of teratogenicity at those doses which were, on a body-weight basis, 15 and 30 times, respectively, the MRHD, and on the basis of body-surface area, 3.1 and 6.2 times, respectively, the MRHD.


The safe use of Dyazide in pregnancy has not been established since there are no adequate and well-controlled studies with Dyazide in pregnant women. Dyazide should be used during pregnancy only if the potential benefit justifies the risk to the fetus.



Triamterene


Reproduction studies have been performed in rats at doses as high as 20 times the MRHD on the basis of body-weight, and 6 times the human dose on the basis of body-surface area without evidence of harm to the fetus due to triamterene.


Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.



Hydrochlorothiazide


Hydrochlorothiazide was orally administered to pregnant mice and rats during respective periods of major organogenesis at doses up to 3,000 and 1,000 mg/kg/day, respectively. At these doses, which are multiples of the MRHD equal to 3,000 for mice and 1,000 for rats, based on body-weight, and equal to 282 for mice and 206 for rats, based on body-surface area, there was no evidence of harm to the fetus.


There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.


 


Nonteratogenic Effects

Thiazides and triamterene have been shown to cross the placental barrier and appear in cord blood. The use of thiazides and triamterene in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, pancreatitis, thrombocytopenia, and possible other adverse reactions which have occurred in the adult.



Nursing Mothers


Thiazides and triamterene in combination have not been studied in nursing mothers. Triamterene appears in animal milk; this may occur in humans. Thiazides are excreted in human breast milk. If use of the combination drug product is deemed essential, the patient should stop nursing.



Pediatric Use


Safety and effectiveness in pediatric patients have not been established.



Adverse Reactions


Adverse effects are listed in decreasing order of severity.



Hypersensitivity


Anaphylaxis, rash, urticaria, subacute cutaneous lupus erythematosus-like reactions, photosensitivity.



Cardiovascular


Arrhythmia, postural hypotension.



Metabolic


Diabetes mellitus, hyperkalemia, hypokalemia, hyponatremia, acidosis, hypercalcemia, hyperglycemia, glycosuria, hyperuricemia, hypochloremia.



Gastrointestinal


Jaundice and/or liver enzyme abnormalities, pancreatitis, nausea and vomiting, diarrhea, constipation, abdominal pain.



Renal


Acute renal failure (one case of irreversible renal failure has been reported), interstitial nephritis, renal stones composed primarily of triamterene, elevated BUN, and serum creatinine, abnormal urinary sediment.



Hematologic


Leukopenia, thrombocytopenia and purpura, megaloblastic anemia.



Musculoskeletal


Muscle cramps.



Central Nervous System


Weakness, fatigue, dizziness, headache, dry mouth.



Miscellaneous


Impotence, sialadenitis.


Thiazides alone have been shown to cause the following additional adverse reactions:



Central Nervous System


Paresthesias, vertigo.



Ophthalmic


Xanthopsia, transient blurred vision.



Respiratory


Allergic pneumonitis, pulmonary edema, respiratory distress.



Other


Necrotizing vasculitis, exacerbation of lupus.



Hematologic


Aplastic anemia, agranulocytosis, hemolytic anemia.



Neonate and infancy


Thrombocytopenia and pancreatitis−rarely, in newborns whose mothers have received thiazides during pregnancy.



Skin


Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis.



Dyazide Dosage and Administration


The usual dose of Dyazide is one or two capsules given once daily, with appropriate monitoring of serum potassium and of the clinical effect (see WARNINGS, Hyperkalemia).



Overdosage


Electrolyte imbalance is the major concern (see WARNINGS section). Symptoms reported include: polyuria, nausea, vomiting, weakness, lassitude, fever, flushed face, and hyperactive deep tendon reflexes. If hypotension occurs, it may be treated with pressor agents such as levarterenol to maintain blood pressure. Carefully evaluate the electrolyte pattern and fluid balance. Induce immediate evacuation of the stomach through emesis or gastric lavage. There is no specific antidote.


Reversible acute renal failure following ingestion of 50 tablets of a product containing a combination of 50 mg triamterene and 25 mg hydrochlorothiazide has been reported. Although triamterene is largely protein-bound (approximately 67%), there may be some benefit to dialysis in cases of overdosage.



How is Dyazide Supplied


Capsules containing 25 mg hydrochlorothiazide and 37.5 mg triamterene, in bottles of 1,000 capsules; in Patient-Pak™ unit-of-use bottles of 100.


They are supplied as follows:


NDC 0007-3650-22–in Patient-Pak™ unit-of-use bottles of 100.


NDC 0007-3650-30–bottles of 1,000.


Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). Protect from light. Dispense in a tight, light-resistant container.


GlaxoSmithKline


Research Triangle Park, NC 27709


Dyazide is a registered trademark of GlaxoSmithKline.


©2011, GlaxoSmithKline. All rights reserved.


February 2011


DYZ:74PI





Principal Display Panel


NDC 0007-3650-30


Dyazide®


25 MG HYDROCHLOROTHIAZIDEAND 37.5 MG TRIAMTERENE


CAPSULES


Rx only


1000 Capsules


Store at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).


Protect from light. Dispense in a tight, light-resistant container.


Each capsule contains 25 mg hydrochlorothiazide and 37.5 mg triamterene.


Dyazide capsules meet Drug Release Test 3 as published in the current USP monograph for Triamterene and Hydrochlorothiazide Capsules.


Usual Dosage: 1or 2 capsules once daily. See accompanying prescribing information.


Important: Use safety closures when dispensing this product unless otherwise directed by physician or requested by purchaser.


GlaxoSmithKline


RTP, NC 27709


Made in Canada


Rev. 7/08


A059478










Dyazide 
hydrochlorothiazide and triamterene  capsule










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0007-3650
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE)HYDROCHLOROTHIAZIDE25 mg
TRIAMTERENE (TRIAMTERENE)TRIAMTERENE37.5 mg






























Inactive Ingredients
Ingredient NameStrength
BENZYL ALCOHOL 
D&C RED NO. 33 
FD&C YELLOW NO. 6 
GELATIN 
GLYCINE 
LACTOSE 
MAGNESIUM STEARATE 
CELLULOSE, MICROCRYSTALLINE 
POVIDONE 
POLYSORBATE 80 
TITANIUM DIOXIDE 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
CETYLPYRIDINIUM CHLORIDE 


















Product Characteristics
ColorRED (opaque red) , WHITE (opaque white)Scoreno score
ShapeCAPSULESize14mm
FlavorImprint CodeDyazide;SB
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10007-3650-22100 CAPSULE In 1 BOTTLENone
20007-3650-301000 CAPSULE In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01604203/30/1994


Labeler - GlaxoSmithKline LLC (167380711)
Revised: 01/2012GlaxoSmithKline LLC

Declomycin


Pronunciation: DEM-e-kloe-SYE-kleen
Generic Name: Demeclocycline
Brand Name: Declomycin


Declomycin is used for:

Treating certain bacterial infections. It may be used in combination with other medicines to treat amoeba infections in the intestines. It may also be used for other conditions as determined by your doctor.


Declomycin is a tetracycline antibiotic. It works by interfering with the production of proteins needed by the bacteria to grow. Slowing the bacteria's growth allows the body's defense mechanisms (eg, white blood cells) to destroy the bacteria.


Do NOT use Declomycin if:


  • you are allergic to any ingredient in Declomycin or another tetracycline (eg, minocycline)

  • you are taking acitretin, isotretinoin, or a penicillin (eg, amoxicillin)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Declomycin:


Some medical conditions may interact with Declomycin. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have kidney or liver problems or diabetes

Some MEDICINES MAY INTERACT with Declomycin. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Acitretin, anticoagulants (eg, warfarin), digoxin, isotretinoin, methotrexate, or methoxyflurane because the risk of their side effects and toxic effects may be increased by Declomycin

  • Penicillins (eg, amoxicillin) or hormonal birth control (eg, birth control pills) because their effectiveness may be decreased by Declomycin

This may not be a complete list of all interactions that may occur. Ask your health care provider if Declomycin may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Declomycin:


Use Declomycin as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Declomycin on an empty stomach at least 1 hour before or 2 hours after eating.

  • Do not take antacids containing aluminum, calcium, or magnesium; bismuth-containing products; iron; urinary alkalinizers (eg, sodium bicarbonate); zinc; or multivitamins with minerals within 2 hours before or 2 hours after taking Declomycin.

  • To clear up your infection completely, take Declomycin for the full course of treatment. Keep taking it even if you feel better in a few days.

  • Drink plenty of fluids with Declomycin to wash it down and avoid the risk of throat irritation.

  • To help prevent throat irritation, do not lie down immediately after taking Declomycin.

  • Do not use Declomycin if it is outdated or has been stored incorrectly.

  • If you miss a dose of Declomycin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Declomycin.



Important safety information:


  • Declomycin may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Declomycin with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Be sure to use Declomycin for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

  • Declomycin only works against bacteria; it does not treat viral infections (eg, the common cold).

  • Long-term or repeated use of Declomycin may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.

  • Hormonal birth control (eg, birth control pills) may not work as well while you are using Declomycin. To prevent pregnancy, use an extra form of birth control (eg, condoms).

  • Mild diarrhea is common with antibiotic use. However, a more serious form of diarrhea, (pseudomembranous colitis) may rarely occur. This may develop while you use the antibiotic or within several months after you stop using it. Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur. Do not treat diarrhea without first checking with your doctor.

  • Declomycin may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Declomycin. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Do not use Declomycin for longer than prescribed without checking with your doctor.

  • Declomycin may interfere with certain lab test results. Be sure your doctor and laboratory personnel know you are using Declomycin.

  • Diabetes patients - Declomycin may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

  • Lab tests, including liver function, kidney function, and complete blood cell counts, may be performed while you use Declomycin. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Declomycin with extreme caution in CHILDREN younger than 10 years old who have diarrhea or an infection of the stomach or bowel.

  • Declomycin is not recommended for use in CHILDREN younger than 8 years of age because permanent tooth discoloration (yellow-gray-brown) may occur.

  • PREGNANCY and BREAST-FEEDING: Declomycin has been shown to cause harm to the fetus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Declomycin during pregnancy. Declomycin is found in breast milk. Do not breast-feed while taking Declomycin.


Possible side effects of Declomycin:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; dizziness; headache; indigestion; loss of appetite; nausea; sensitivity to sunlight; throat irritation; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody stools; blurred vision; dark urine; decreased or increased urination; fever, chills, or sore throat; increased thirst; muscle weakness; red, swollen, blistered, or peeling skin; severe diarrhea; severe or persistent headache; severe or persistent throat irritation; severe skin reaction to the sun; stomach pain or cramps; unusual bruising or bleeding; unusual tiredness; vaginal irritation or discharge; vision changes; weakness; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Declomycin side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Declomycin:

Store Declomycin at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Declomycin out of the reach of children and away from pets.


General information:


  • If you have any questions about Declomycin, please talk with your doctor, pharmacist, or other health care provider.

  • Declomycin is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Declomycin. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Declomycin resources


  • Declomycin Side Effects (in more detail)
  • Declomycin Use in Pregnancy & Breastfeeding
  • Drug Images
  • Declomycin Drug Interactions
  • Declomycin Support Group
  • 2 Reviews for Declomycin - Add your own review/rating


  • Declomycin Monograph (AHFS DI)

  • Declomycin Concise Consumer Information (Cerner Multum)

  • Demeclocycline Prescribing Information (FDA)

  • Demeclocycline Professional Patient Advice (Wolters Kluwer)



Compare Declomycin with other medications


  • SIADH

Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical


Generic Name: salicylic acid (Topical route)


sal-i-SIL-ik AS-id


Commonly used brand name(s)

In the U.S.


  • Akurza

  • Aliclen

  • Avosil

  • Betasal

  • Compound W

  • Corn Removing

  • Dermarest Psoriasis

  • DHS Sal

  • Drytex

  • Duofilm

  • Duoplant

  • Durasal

  • Freezone

  • Fung-O

  • Gets-It Corn/Callus Remover

  • Gordofilm

  • Hydrisalic

  • Ionil

  • Ionil Plus

  • Keralyt

  • Keralyt Scalp

  • Lupicare

  • Mediplast

  • Mg217 Sal-Acid

  • Mosco Corn & Callus Remover

  • Neutrogena

  • Occlusal-HP

  • Off-Ezy

  • Oxy Balance

  • P & S

  • Palmer's Skin Success Acne Cleanser

  • Propa pH

  • Salac

  • Sal-Acid Plaster

  • Salactic Film

  • Salex

  • Salitop

  • Salkera

  • Sal-Plant Gel

  • Salvax

  • Seba-Clear

  • Stri-Dex

  • Thera-Sal

  • Therasoft Anti-Acne

  • Tinamed

  • Ti-Seb

  • Virasal

  • Wart-Off Maximum Strength

  • Zapzyt

In Canada


  • Acnex

  • Acnomel Acne Mask

  • Clear Away Wart Removal System

  • Compound W One-Step Wart Remover

  • Compound W Plus

  • Dr. Scholl's Clear Away One Step Plantar Wart Remover

  • Dr. Scholl's Cushlin Ultra Slim Callus Removers

  • Dr. Scholl's Cushlin Ultra Slim Corn Removers

  • Duoforte 27

  • Freezone - One Step Callus Remover Pad

  • Freezone - One Step Corn Remover Pad

Available Dosage Forms:


  • Soap

  • Lotion

  • Liquid

  • Foam

  • Ointment

  • Gel/Jelly

  • Solution

  • Cream

  • Pad

  • Paste

  • Shampoo

  • Dressing

  • Stick

Therapeutic Class: Antiacne


Pharmacologic Class: NSAID


Chemical Class: Salicylate, Non-Aspirin


Uses For Dr. Scholl's Cushlin Ultra Slim Callus Removers


Salicylic acid is used to treat many skin disorders, such as acne, dandruff, psoriasis, seborrheic dermatitis of the skin and scalp, calluses, corns, common warts, and plantar warts, depending on the dosage form and strength of the preparation.


Some of these preparations are available only with your doctor's prescription.


Before Using Dr. Scholl's Cushlin Ultra Slim Callus Removers


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Young children may be at increased risk of unwanted effects because of increased absorption of salicylic acid through the skin. Also, young children may be more likely to get skin irritation from salicylic acid. Salicylic acid should not be applied to large areas of the body, used for long periods of time, or used under occlusive dressing (air-tight covering, such as kitchen plastic wrap) in infants and children. Salicylic acid should not be used in children younger than 2 years of age.


Geriatric


Elderly people are more likely to have age-related blood vessel disease. This may increase the chance of problems during treatment with this medicine.


Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Abciximab

  • Argatroban

  • Bivalirudin

  • Cilostazol

  • Citalopram

  • Clovoxamine

  • Dabigatran Etexilate

  • Dipyridamole

  • Escitalopram

  • Femoxetine

  • Flesinoxan

  • Fluoxetine

  • Fluvoxamine

  • Fondaparinux

  • Heparin

  • Lepirudin

  • Nefazodone

  • Paroxetine

  • Protein C

  • Rivaroxaban

  • Sertraline

  • Sibutramine

  • Ticlopidine

  • Tirofiban

  • Vilazodone

  • Zimeldine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Acenocoumarol

  • Anisindione

  • Ardeparin

  • Azilsartan Medoxomil

  • Azosemide

  • Bemetizide

  • Bendroflumethiazide

  • Benzthiazide

  • Bumetanide

  • Buthiazide

  • Candesartan Cilexetil

  • Certoparin

  • Chlorothiazide

  • Chlorthalidone

  • Clopamide

  • Cyclopenthiazide

  • Dalteparin

  • Danaparoid

  • Dicumarol

  • Enoxaparin

  • Eprosartan

  • Ethacrynic Acid

  • Furosemide

  • Hydrochlorothiazide

  • Hydroflumethiazide

  • Indapamide

  • Irbesartan

  • Losartan

  • Methyclothiazide

  • Metolazone

  • Nadroparin

  • Olmesartan Medoxomil

  • Parnaparin

  • Phenindione

  • Phenprocoumon

  • Piretanide

  • Polythiazide

  • Probenecid

  • Reviparin

  • Tamarind

  • Tasosartan

  • Telmisartan

  • Tinzaparin

  • Torsemide

  • Trichlormethiazide

  • Valsartan

  • Warfarin

  • Xipamide

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Blood vessel disease

  • Diabetes mellitus (sugar diabetes)—Use of this medicine may cause severe redness or ulceration, especially on the hands or feet

  • Inflammation, irritation, or infection of the skin—Use of this medicine may cause severe irritation if applied to inflamed, irritated, or infected area of the skin

  • Influenza (flu) or

  • Varicella (chicken pox)—This medicine should not be used in children and teenagers with the flu or chicken pox. There is a risk of Reye's syndrome.

  • Kidney disease or

  • Liver disease—Using this medicine for a long time over large areas could result in unwanted effects

Proper Use of salicylic acid

This section provides information on the proper use of a number of products that contain salicylic acid. It may not be specific to Dr. Scholl's Cushlin Ultra Slim Callus Removers. Please read with care.


It is very important that you use this medicine only as directed. Do not use more of it, do not use it more often, and do not use it for a longer time than recommended on the label, unless otherwise directed by your doctor. To do so may increase the chance of absorption through the skin and the chance of salicylic acid poisoning.


If your doctor has ordered an occlusive dressing (airtight covering, such as kitchen plastic wrap) to be applied over this medicine, make sure you know how to apply it. Since an occlusive dressing will increase the amount of medicine absorbed through your skin and the possibility of salicylic acid poisoning, use it only as directed. If you have any questions about this, check with your doctor.


Keep this medicine away from the eyes and other mucous membranes, such as the mouth and inside of the nose. If you should accidentally get some in your eyes or on other mucous membranes, immediately flush them with water for 15 minutes.


To use the cream, lotion, or ointment form of salicylic acid:


  • Apply enough medicine to cover the affected area, and rub in gently.

To use the gel form of salicylic acid:


  • Before using salicylic acid gel, apply wet packs to the affected areas for at least 5 minutes. If you have any questions about this, check with your health care professional.

  • Apply enough gel to cover the affected areas, and rub in gently.

To use the pad form of salicylic acid:


  • Wipe the pad over the affected areas.

  • Do not rinse off medicine after treatment.

To use the plaster form of salicylic acid for warts, corns, or calluses:


  • This medicine comes with patient instructions. Read them carefully before using.

  • Do not use this medicine on irritated skin or on any area that is infected or reddened. Also, do not use this medicine if you are a diabetic or if you have poor blood circulation.

  • Do not use this medicine on warts with hair growing from them or on warts on the face, in or on the genital (sex) organs, or inside the nose or mouth. Also do not use on moles or birthmarks. To do so may cause severe irritation.

  • Wash the area to be treated and dry thoroughly. Warts may be soaked in warm water for 5 minutes before drying.

  • Cut the plaster to fit the wart, corn, or callus and apply.

  • For corns and calluses:
    • Repeat every 48 hours as needed for up to 14 days, or as directed by your doctor, until the corn or callus is removed.

    • Corns or calluses may be soaked in warm water for 5 minutes to help in their removal.


  • For warts:
    • Depending on the product, either:
      • Apply plaster and repeat every 48 hours as needed, or
        • Apply plaster at bedtime, leave in place for at least 8 hours, remove plaster in the morning, and repeat every 24 hours as needed.



    • Repeat for up to 12 weeks as needed, or as directed by your doctor, until wart is removed.


  • If discomfort gets worse during treatment or continues after treatment, or if the wart spreads, check with your doctor.

To use the shampoo form of salicylic acid:


  • Before applying this medicine, wet the hair and scalp with lukewarm water. Apply enough medicine to work up a lather and rub well into the scalp for 2 or 3 minutes, then rinse. Apply the medicine again and rinse thoroughly.

To use the soap form of salicylic acid:


  • Work up a lather with the soap, using hot water, and scrub the entire affected area with a washcloth or facial sponge or mitt.

  • If you are to use this soap in a foot bath, work up rich suds in hot water and soak the feet for 10 to 15 minutes. Then pat dry without rinsing.

To use the topical solution form of salicylic acid for acne:


  • Wet a cotton ball or pad with the topical solution and wipe the affected areas.

  • Do not rinse off medicine after treatment.

To use the topical solution form of salicylic acid for warts, corns, or calluses:


  • This medicine comes with patient instructions. Read them carefully before using.

  • This medicine is flammable. Do not use it near heat or open flame or while smoking.

  • Do not use this medicine on irritated skin or on any area that is infected or reddened. Also, do not use this medicine if you are a diabetic or if you have poor blood circulation.

  • Do not use this medicine on warts with hair growing from them or on warts on the face, in or on the genital (sex) organs, or inside the nose or mouth. Also do not use on moles or birthmarks. To do so may cause severe irritation.

  • Avoid breathing in the vapors from the medicine.

  • Wash the area to be treated and dry thoroughly. Warts may be soaked in warm water for 5 minutes before drying.

  • Apply the medicine one drop at a time to completely cover each wart, corn, or callus. Let dry.

  • For warts—Repeat one or two times a day as needed for up to 12 weeks, or as directed by your doctor, until wart is removed.

  • For corns and calluses—Repeat one or two times a day as needed for up to 14 days, or as directed by your doctor, until the corn or callus is removed.

  • Corns and calluses may be soaked in warm water for 5 minutes to help in their removal.

  • If discomfort gets worse during treatment or continues after treatment, or if the wart spreads, check with your doctor.

Unless your hands are being treated, wash them immediately after applying this medicine to remove any medicine that may be on them.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For cream dosage form:
    • For corns and calluses:
      • Adults and children—Use the 2 to 10% cream as needed. Use the 25 to 60% cream one time every three to five days.



  • For gel dosage form:
    • For acne:
      • Adults and children—Use the 0.5 to 5% gel one time a day.


    • For psoriasis:
      • Adults and children—Use the 5% gel one time a day.


    • For common warts:
      • Adults and children—Use the 5 to 26% gel one time a day.



  • For lotion dosage form:
    • For acne:
      • Adults and children—Use the 1 to 2% lotion one to three times a day.


    • For dandruff and antiseborrhic dermatitis of the scalp:
      • Adults and children—Use the 1.8 to 2% lotion on the scalp one or two times a day.



  • For ointment dosage form:
    • For acne:
      • Adults and children—Use the 3 to 6% ointment as needed.


    • For psoriasis and seborrheic dermatitis:
      • Adults and children—Use the 3 to 10% ointment as needed.


    • For common warts:
      • Adults and children—Use the 3 to 10% ointment as needed. Use the 25 to 60% ointment one time every three to five days.



  • For pads dosage form:
    • For acne:
      • Adults and children—Use one to three times a day.



  • For plaster dosage form:
    • For corns, calluses, common warts, or plantar warts:
      • Adults and children—Use one time a day or one time every other day.



  • For shampoo dosage form:
    • For dandruff or seborrheic dermatitis of the scalp:
      • Adults and children—Use on the scalp one or two times a week.



  • For soap dosage form:
    • For acne:
      • Adults and children—Use as needed.



  • For topical solution dosage form:
    • For acne:
      • Adults and children—Use the 0.5 to 2% topical solution one to three times a day.


    • For common warts and plantar warts:
      • Adults and children—Use the 5 to 27% topical solution one or two times a day.


    • For corns and calluses:
      • Adults and children—Use the 12 to 27% topical solution one or two times a day.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Dr. Scholl's Cushlin Ultra Slim Callus Removers


When using salicylic acid, do not use any of the following preparations on the same affected area as this medicine, unless otherwise directed by your doctor:


  • Abrasive soaps or cleansers

  • Alcohol-containing preparations

  • Any other topical acne preparation or preparation containing a peeling agent (for example, benzoyl peroxide, resorcinol, sulfur, or tretinoin [vitamin A acid])

  • Cosmetics or soaps that dry the skin

  • Medicated cosmetics

  • Other topical medicine for the skin

To use any of the above preparations on the same affected area as salicylic acid may cause severe irritation of the skin.


Check with your doctor right away if you have nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy hyperpnea, diarrhea, and psychic disturbances. These could be symptoms of a serious condition called salicylate toxicity, especially in children under 12 years of age and patients with kidney or liver problems.


Dr. Scholl's Cushlin Ultra Slim Callus Removers Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Less common or rare
  • Skin irritation not present before use of this medicine (moderate or severe)

Frequency not known
  • Dryness and peeling of skin

  • flushing

  • redness of skin

  • unusually warm skin

Symptoms of salicylic acid poisoning
  • Confusion

  • diarrhea

  • dizziness

  • fast or deep breathing

  • headache (severe or continuing)

  • hearing loss

  • lightheadedness

  • nausea

  • rapid breathing

  • ringing or buzzing in ears (continuing)

  • severe drowsiness

  • stomach pain

  • vomiting

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Skin irritation not present before use of this medicine (mild)

  • stinging

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical resources


  • Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical Side Effects (in more detail)
  • Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical Use in Pregnancy & Breastfeeding
  • Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical Drug Interactions
  • Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical Support Group
  • 1 Review for Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical - Add your own review/rating


Compare Dr. Scholl's Cushlin Ultra Slim Callus Removers Topical with other medications


  • Acne
  • Dermatological Disorders
  • Warts

Daytrana transdermal


Generic Name: methylphenidate (transdermal) (meth il FEN ih date)

Brand Names: Daytrana


What is methylphenidate transdermal?

Methylphenidate is a central nervous system stimulant. In affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control.


Methylphenidate is used to treat attention deficit hyperactivity disorder (ADHD).


Methylphenidate may also be used for purposes not listed in this medication guide.


What is the most important information I should know about methylphenidate transdermal?


Do not use methylphenidate if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Do not use this medication if you are allergic to methylphenidate or if you have glaucoma, tics (muscle twitches) or Tourette's syndrome, or severe anxiety, tension, or agitation (methylphenidate can make these symptoms worse). Methylphenidate is a drug of abuse and may be habit-forming. Keep track of how many patches have been used from each new package you receive. You should be aware if anyone is using your medicine improperly or without a prescription. Using this medication improperly can cause death or serious side effects on the heart. Keep track of the amount of patches used from each new package. Methylphenidate is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription. Using this medication improperly can cause death or serious side effects on the heart. Children using this medication should be warned never to remove the skin patch and place it onto another person. Serious side effects may result.

What should I discuss with my health care provider before using methylphenidate transdermal?


Do not use methylphenidate if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days.

Do not use this medication if you are allergic to methylphenidate or if you have:



  • glaucoma;




  • a personal or family history of tics (muscle twitches) or Tourette's syndrome;




  • severe anxiety, tension, or agitation (methylphenidate can make these symptoms worse); or




  • if you have ever had a skin reaction when using any type of adhesive bandage or transdermal skin patch.




Some stimulants have caused sudden death in children and adolescents with serious heart problems or congenital heart defects. To make sure you can safely use methylphenidate, tell your doctor if you have any of these other conditions:

  • a congenital heart defect;




  • high blood pressure, heart failure, heart rhythm disorder, or recent heart attack;




  • a personal or family history of mental illness, psychotic disorder, bipolar illness, depression, or suicide attempt;




  • epilepsy or other seizure disorder;




  • a skin condition such as eczema or psoriasis; or




  • a history of drug or alcohol addiction.




Methylphenidate may be habit-forming and should be used only by the person it was prescribed for. Never share this medication with another person, especially someone with a history of drug abuse or addiction. FDA pregnancy category C. It is not known whether methylphenidate will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is not known whether methylphenidate passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Long-term use of methylphenidate can slow a child's growth. Tell your doctor if the child using this medication is not growing or gaining weight properly.


Do not use methylphenidate transdermal on a child younger than 6 years old without the advice of a doctor.

How should I use methylphenidate transdermal?


Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.


To use the patch, open the sealed pouch and remove the protective liner. Press the patch onto the skin and press it down with the palm of your hand for about 30 seconds. Make sure the patch is well sealed around the edges. When properly applied, the patch should stay on while swimming or bathing.


Apply the patch to an area on the hip that is clean and dry. Avoid skin that is oily, irritated, or damaged. Avoid a skin area that will be rubbed by a waistband or tight clothing. The next morning, apply a new patch to the opposite hip. Do not wear a patch on the same side of the body two days in a row.


The effects of this medicine should be noticeable within 2 hours after applying the skin patch. Remove the patch 9 hours after it was applied.


If the patch falls off, replace it with a new one. Then remove the new patch after it has been 9 hours since you applied the first patch. Your patch wearing time should be no more than 9 hours per day, even if you apply a new patch to replace one that has fallen off.


After removing a patch, fold it in half so it sticks together and flush it down the toilet or place it in a waste can with a lid. If you stop using this medicine and have any unused patches leftover, throw each patch away using this same method.


Methylphenidate transdermal patches come with a chart to keep track of when the patches are applied and removed. A time chart is also included to help you estimate what time to remove a patch based on what time it is applied.


If you have sleep problems (insomnia) or loss of appetite in the evenings, try removing the skin patch earlier in the day. Never cut the skin patch to try and reduce the amount of medicine you receive while wearing it.


Do not expose the skin patch to heat while you are wearing it. This includes heat from a heating pad, hot tub, electric blanket, or a heated water bed. Heat can cause the skin patch to release too much medicine at one time.


Keep the methylphenidate transdermal patch in its sealed pouch until you are ready to use it. Store at room temperature away from heat and moisture. Throw away any unused patches that are left over if it has been more than 30 days since you opened the original package. Methylphenidate is a drug of abuse and may be habit-forming. Keep track of how many patches have been used from each new package you receive. You should be aware if anyone is using your medicine improperly or without a prescription. Using this medication improperly can cause death or serious side effects on the heart. Children using this medication should be warned never to remove the skin patch and place it onto another person. Serious side effects may result.

What happens if I miss a dose?


Apply a patch as soon as you remember, and do not wear the patch for longer than 9 hours. You may need to shorten the wearing time to less than 9 hours if you apply a patch later than usual and you have sleep problems. Do not apply two patches at the same time to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Remove the patch right away and clean the skin area with soap and water. An overdose of methylphenidate can be fatal.

Overdose symptoms may include vomiting, agitation, tremors, muscle twitching, seizure (convulsions), confusion, hallucinations, sweating, fast or pounding heartbeat, blurred vision, dry mouth and nose, and fainting.


What should I avoid while using methylphenidate transdermal?


Methylphenidate may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Do not apply a patch late in the day. A patch applied too late in the day can cause sleep problems (insomnia).


Methylphenidate transdermal side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using methylphenidate and call your doctor at once if you have a serious side effect such as:

  • fast, pounding, or uneven heartbeats, feeling light-headed, fainting;




  • increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure);




  • redness, swelling, itching, or blistering where the skin patch was worn (may also spread to other areas);




  • headache with fever, weakness, joint pain, diarrhea, and/or vomiting;




  • aggression, restlessness, hallucinations, unusual behavior, or motor tics (muscle twitches); or




  • confusion, crying, feeling irritable.



Less serious side effects may include:



  • vision problems;




  • mild skin redness, bumps, or itching;




  • nausea, vomiting, loss of appetite, weight loss;




  • sleep problems (insomnia); or




  • stuffy nose, sore throat.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect methylphenidate transdermal?


Tell your doctor about all other medicines you use, especially:



  • clonidine (Catapres) or other blood pressure medications;




  • a blood thinner such as warfarin (Coumadin);




  • seizure medicine such as phenytoin (Dilantin), phenobarbital (Luminal), primidone (Mysoline); or




  • an antidepressant such as clomipramine (Anafranil), desipramine (Norpramin), imipramine (Tofranil), citalopram (Celexa), fluoxetine (Prozac, Sarafem), paroxetine (Paxil), and others.



This list is not complete and other drugs may interact with methylphenidate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Daytrana resources


  • Daytrana Side Effects (in more detail)
  • Daytrana Use in Pregnancy & Breastfeeding
  • Daytrana Drug Interactions
  • Daytrana Support Group
  • 27 Reviews for Daytrana - Add your own review/rating


Compare Daytrana with other medications


  • ADHD


Where can I get more information?


  • Your pharmacist can provide more information about methylphenidate transdermal.

See also: Daytrana side effects (in more detail)


D.H.E. 45 injection


Generic Name: dihydroergotamine (injection) (dye HYE droe er GOT a meen)

Brand Names: D.H.E. 45


What is D.H.E. 45 (dihydroergotamine (injection))?

Dihydroergotamine is in a group of drugs called ergot alkaloids (ER-got AL-ka-loids). It works by narrowing the blood vessels around the brain and affects blood flow patterns that are associated with certain types of headaches.


Dihydroergotamine injection is used to treat a migraine or cluster headache attack. This medication will only treat a headache that has already begun. It will not prevent headaches or reduce the number of attacks.


Dihydroergotamine injection should not be used to treat common tension headaches or any headache that seems to be different from your usual migraine headaches. Dihydroergotamine is not for daily use.

Dihydroergotamine injection may also be used for purposes not listed in this medication guide.


What is the most important information I should know about D.H.E. 45 (dihydroergotamine (injection))?


This medication can harm an unborn baby or a nursing baby. Do not use if you are pregnant or breast-feeding. Using certain medications together with dihydroergotamine can cause even greater decreases in blood flow than dihydroergotamine used alone, which can lead to dangerous side effects. Tell your doctor about all other medications you are using.

Also tell your doctor about all of your medical conditions, especially breathing problems, high blood pressure, ischemic bowel disease, liver or kidney disease, or risk factors for heart disease.


Never use more than your prescribed dose of dihydroergotamine. An overdose can be fatal.

What should I discuss with my healthcare provider before using D.H.E. 45 (dihydroergotamine (injection))?


Do not use this medication if you are allergic to dihydroergotamine or other ergot medicine such as Ergomar, Cafergot, Migergot, Migranal, or Methergine. Do not use dihydroergotamine injection if you are pregnant or breast-feeding, or if you have:

  • a history of heart disease, angina (chest pain), blood circulation problems, or history of a heart attack or stroke;




  • coronary artery disease or "hardening of the arteries";




  • uncontrolled high blood pressure;




  • severe liver or kidney disease;




  • a serious infection called sepsis; or




  • if you have recently had heart or blood vessel surgery (such as bypass surgery).




Using certain medications together with dihydroergotamine can cause even greater decreases in blood flow than dihydroergotamine used alone, which can lead to dangerous side effects. Do not use dihydroergotamine if you are also using any of the following medications:

  • conivaptan (Vaprisol), imatinib (Gleevec), isoniazid (for treating tuberculosis), or nefazodone (an antidepressant);




  • diclofenac (Arthrotec, Cataflam, Voltaren, Flector Patch, Solareze);




  • clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), or telithromycin (Ketek);




  • clotrimazole (Mycelex Troche), itraconazole (Sporanox), ketoconazole (Extina, Ketozole, Nizoral, Xolegal), or voriconazole (Vfend);




  • heart or blood pressure medication such as diltiazem (Cardizem, Dilacor, Tiazac), nicardipine (Cardene), quinidine (Quin-G), or verapamil (Calan, Covera, Isoptin, Verelan); or




  • HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase, Fortovase), or ritonavir (Norvir).



Dihydroergotamine can cause rare but serious side effects on the heart, including heart attack or stroke. To make sure you can safely take dihdroergotamine, tell your doctor if you have any of these other conditions:



  • breathing problems;




  • high blood pressure;




  • ischemic bowel disease;




  • liver or kidney disease; or




  • coronary heart disease (or risk factors that include diabetes, menopause, smoking, being overweight, having high blood pressure or high cholesterol, having a family history of coronary artery disease, being older than 40 and a man, or being a woman who has had a hysterectomy).




FDA pregnancy category X. Dihydroergotamine can cause birth defects. Do not use if you are pregnant. Tell your doctor right away if you become pregnant during treatment. Use an effective form of birth control while you are using this medication. Dihydroergotamine can pass into breast milk and may harm a nursing baby. Dihydroergotamine may also decrease milk production. Do not use if you are breast-feeding a baby.

How should I use D.H.E. 45 (dihydroergotamine (injection))?


Use exactly as prescribed by your doctor. Never use more than your prescribed dose of dihydroergotamine. Tell your doctor if the medicine seems to stop working as well in treating your migraine attacks.


Dihydroergotamine is injected into a muscle. You may be shown how to use injections at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles and syringes.


Use dihydroergotamine injection as soon as you notice headache symptoms, or after an attack has already begun.


If your headache does not completely go away, you may use a second injection after 1 hour has passed, and a third injection if needed after another hour has passed (a total of 3 injections).


If you still have migraine symptoms after using 3 injections, call your doctor before using any more. If your headache goes away and then comes back, you may use the medication again if it has been at least 6 hours since your last injection.

Do not use more than a total of 3 injections of this medication in any 24-hour period. Do not use more than a total of 6 injections over a period of 7 days.


Dihydroergotamine injection should be clear and colorless. Do not use if the liquid has changed colors or has particles in it. Call your doctor for a new prescription.


If you use dihydroergotamine long-term, your doctor may want to check your heart function periodically using an electrocardiograph or ECG (sometimes called an EKG), a machine that measures electrical activity of the heart.


Store at room temperature away from moisture, heat, and light. Do not use if the expiration date on the label has passed.

What happens if I miss a dose?


Since dihydroergotamine is used on an as-needed basis, you are not likely to miss a dose. Do not use more than 3 injections of dihydroergotamine per day or more than 6 injections per week.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of dihydroergotamine can be fatal. Overdose symptoms may include some of the serious side effects listed in this medication guide.

What should I avoid while using D.H.E. 45 (dihydroergotamine (injection))?


Do not use dihydroergotamine injection within 24 hours before or after using another migraine headache medicine, including:

  • another ergot medicine such as ergotamine (Ergomar, Cafergot, Migergot), dihydroergotamine (Migranal), or methylergonovine (Methergine); or




  • almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), sumatriptan (Imitrex), rizatriptan (Maxalt, Maxalt-MLT), or zolmitriptan (Zomig).



Grapefruit and grapefruit juice may interact with dihydroergotamine injection and lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor.


D.H.E. 45 (dihydroergotamine (injection)) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using dihydroergotamine and call your doctor at once if you have a serious side effect such as:

  • fast or slow heart rate, swelling or itching in any part of your body;




  • chest pain spreading to the arm or shoulder, and nausea, sweating, or general ill feeling;




  • sudden numbness or weakness, sudden headache, confusion, or problems with vision, speech, or balance;




  • leg weakness, muscle pain in your arms or legs;




  • numbness, tingling, and a pale or blue-colored appearance in your fingers or toes;




  • stomach cramps, diarrhea that may be bloody;




  • cough with stabbing chest pain and trouble breathing; or




  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath).



Less serious side effects may include:



  • headache, dizziness, feeling anxious;




  • diarrhea;




  • sweating, mild skin rash, redness or tingly feeling under your skin.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect D.H.E. 45 (dihydroergotamine (injection))?


Many drugs can interact with dihydroergotamine. Below is just a partial list. Tell your doctor if you are using:



  • zileuton (Zyflo);




  • nicotine (Nicoderm, Nicorette);




  • cold or allergy medications, diet pills, stimulants, or medication to treat ADHD (such as Ritalin or Adderall);




  • an antidepressant such fluoxetine (Prozac), sertraline (Zoloft), and others;




  • fluconazole (Diflucan) or other antifungal medication; or




  • heart or blood pressure medication such as atenolol (Tenormin), carvedilol (Coreg), metoprolol (Lopressor, Toprol), propranolol (Inderal, InnoPran), and others.



This list is not complete and other drugs may interact with dihydroergotamine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More D.H.E. 45 resources


  • D.H.E. 45 Side Effects (in more detail)
  • D.H.E. 45 Use in Pregnancy & Breastfeeding
  • D.H.E. 45 Drug Interactions
  • D.H.E. 45 Support Group
  • 3 Reviews for D.H.E. 45 - Add your own review/rating


Compare D.H.E. 45 with other medications


  • Cluster Headaches
  • Migraine


Where can I get more information?


  • Your pharmacist can provide more information about dihydroergotamine injection.

See also: D.H.E. 45 side effects (in more detail)